Literature DB >> 23553047

Comparison of four target volume definitions for pancreatic cancer. Guidelines for treatment of the lymphatics and the primary tumor.

E Fokas1, C Eccles, N Patel, K-Y Chu, S Warren, W Gillies McKenna, T B Brunner.   

Abstract

BACKGROUND AND
PURPOSE: Target volume definitions for radiotherapy in pancreatic ductal adenocarcinoma (PDAC) vary substantially. Some groups aim to treat the primary tumor only, whereas others include elective lymph nodes (eLNs). eLNs close to the primary tumor are often included unintentionally within the treatment volume, depending on the respective treatment philosophies. We aimed to measure the percentages of anatomical coverage of eLNs by comparing four different contouring guidelines. PATIENTS AND METHODS: Planning target volumes (PTVs) were contoured using planning computed tomography (CT) scans of 11 patients with PDAC based on the Oxford, RTOG (Radiation Therapy Oncology Group), Michigan, and SCALOP (Selective Chemoradiation in Advanced Localised Pancreatic Cancer trial) guidelines. Clinical target volumes (CTVs) included the peripancreatic, para-aortic, paracaval, celiac trunk, superior mesenteric, and portal vein lymph node areas. Volumetric comparisons of the coverage of all eLN regions were conducted to illustrate the differences between the four contouring strategies.
RESULTS: The PTV sizes of the RTOG and Oxford guidelines were comparable. The SCALOP and Michigan PTV sizes were similar to each other and significantly smaller than the RTOG and Oxford PTVs. A large variability of eLN coverage was found for the various subregions according to the respective contouring strategies.
CONCLUSION: This is the first study to directly compare the percentage of anatomical coverage of eLNs according to four PTVs in the same patient cohort. Potential practical consequences are discussed in detail.

Entities:  

Mesh:

Year:  2013        PMID: 23553047     DOI: 10.1007/s00066-013-0332-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  24 in total

1.  Radiotherapy: the importance of local control in pancreatic cancer.

Authors:  Edgar Ben-Josef; Theodore S Lawrence
Journal:  Nat Rev Clin Oncol       Date:  2011-11-29       Impact factor: 66.675

2.  Large topographic variability of upper abdominal lymphatics and the consequences for radiation treatment planning.

Authors:  Thomas B Brunner; Ulrich Baum; Gerhard G Grabenbauer; Rolf Sauer; Ulrike Lambrecht
Journal:  Radiother Oncol       Date:  2006-10-16       Impact factor: 6.280

3.  Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis.

Authors:  Thomas B Brunner; Susanne Merkel; Gerhard G Grabenbauer; Thomas Meyer; Ulrich Baum; Thomas Papadopoulos; Rolf Sauer; Werner Hohenberger
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-15       Impact factor: 7.038

4.  Volumetric modulated arc therapy for advanced pancreatic cancer.

Authors:  Wietse Eppinga; Frank Lagerwaard; Wilko Verbakel; Ben Slotman; Suresh Senan
Journal:  Strahlenther Onkol       Date:  2010-06-24       Impact factor: 3.621

5.  Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions.

Authors:  Aaron C Spalding; Kyung-Wook Jee; Karen Vineberg; Marla Jablonowski; Benedick A Fraass; Charlie C Pan; Theodore S Lawrence; Randall K Ten Haken; Edgar Ben-Josef
Journal:  Med Phys       Date:  2007-02       Impact factor: 4.071

6.  Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence.

Authors:  Wenjie Sun; Cheng N Leong; Zhen Zhang; Jiade J Lu
Journal:  Radiat Oncol       Date:  2010-04-15       Impact factor: 3.481

Review 7.  Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

Authors:  Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff
Journal:  PLoS Med       Date:  2010-04-20       Impact factor: 11.069

8.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Authors:  Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

9.  [Database supported electronic retrospective analyses in radiation oncology: establishing a workflow using the example of pancreatic cancer].

Authors:  K A Kessel; D Habermehl; C Bohn; A Jäger; R O Floca; L Zhang; N Bougatf; R Bendl; J Debus; S E Combs
Journal:  Strahlenther Onkol       Date:  2012-10-31       Impact factor: 3.621

Review 10.  Radiotherapy in pancreatic cancer.

Authors:  Gunther Klautke; Thomas B Brunner
Journal:  Strahlenther Onkol       Date:  2008-11-19       Impact factor: 3.621

View more
  4 in total

1.  Role of radiotherapy in the chemotherapy-containing multidisciplinary management of patients with resected pancreatic adenocarcinoma.

Authors:  Claudio V Sole; Felipe A Calvo; Freddy Atahualpa; Alejandro Berlin; Rafael Herranz; Luis Gonzalez-Bayon; Jose Luis García-Sabrido
Journal:  Strahlenther Onkol       Date:  2014-10-08       Impact factor: 3.621

2.  Successful radiation treatment of chylous ascites following pancreaticoduodenectomy.

Authors:  Stefanie Corradini; Sylke Liebig; Olivier M Niemoeller; Felix Zwicker; Wolfram Lamadé
Journal:  Strahlenther Onkol       Date:  2015-01-10       Impact factor: 3.621

3.  Endobiliary Stent Position Changes during External-beam Radiotherapy.

Authors:  Kwun-Ye Chu; Cynthia L Eccles; Thomas B Brunner
Journal:  J Med Imaging Radiat Sci       Date:  2015-03

4.  Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.

Authors:  Henriette Golcher; Thomas B Brunner; Helmut Witzigmann; Lukas Marti; Wolf-Otto Bechstein; Christiane Bruns; Henry Jungnickel; Stefan Schreiber; Gerhard G Grabenbauer; Thomas Meyer; Susanne Merkel; Rainer Fietkau; Werner Hohenberger
Journal:  Strahlenther Onkol       Date:  2014-09-25       Impact factor: 3.621

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.